Tagged with US

Artificial Intelligence On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when drug development had been becoming financially unsustainable and clinical research organisations (CROs) had been systematically failing to improve operational efficiency.…

Artificial Intelligence The AI in Life Sciences Market was valued at USD 902.1 million in 2019 by Mordor Intelligence and is projected to expand at an impressive 20 percent compound annual growth rate in the period 2020 to 2024. Yet despite the massive hype and enthusiasm around artificial intelligence’s propensity to positively…

Russia The top 10 pharmaceutical companies in the Russian hospital market for the nine months up to November 2019, sorted by percentage share of total hospital purchases. Domestic player Biocad leads the way, followed by global firms MSD and Pfizer.   Made with Visme Infographic Maker     The top 10…

USA Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect.   Pharma is unlikely to be frog-marched by sweeping federal initiatives, but more incremental changes are likely With anti-pharma sentiment raging at the end of 2018,…

USA Matt Eyles, president and CEO of the Association of Healthcare Insurance Providers (AHIP) outlines how the US health insurance landscape has evolved in the last ten years, counters some of the pharmaceutical industry’s criticisms of insurance firms, and outlines why greater affordability of healthcare in the US will benefit all…

Facts A snapshot of the latest data on the French pharmaceutical industry from industry association LEEM, including market revenues, R&D investments, employment and consumption. Made with Visme Presentation Maker

USA In 2019, the US FDA’s Center for Drug Evaluation and Research approved 42 novel drugs, down from 59 drugs approved in 2018. Novartis had four drugs approved, the highest number from any single pharma company. 16 of the 42, or 38 per cent, received orphan drug designation. This listing does…

Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…

Russia Nadezhda Fedotova and Andrey Zelenin of Lidings law firm gives an update on recent amendments to the labeling legislation for medicines in Russia, their potential impact on the Russian pharmaceutical industry, and the numerous uncertainties still remaining.   Despite the time moving up to January 1, 2020, it seems impossible…

USA Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption,  data-driven demands and convenient care delivery.   Throughout my career, to bring positive and lasting change to the health sector, I’ve brokered more collaborative efforts than I can count. Strategic alliances between health leaders, nonprofit…

UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…

USA Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be taken to remedy the situation.   Globally, 700,000 people lose their lives to drug-resistant infections each year In November 2019,…